Literature DB >> 12641517

The prophylactic use of a proton pump inhibitor before food and alcohol.

C O'Leary1, J McCarthy, M Humphries, F Shanahan, E Quigley.   

Abstract

BACKGROUND: Patients report that the prophylactic consumption of a proton pump inhibitor minimizes gastrointestinal symptoms expected to be provoked by late-night food and alcohol consumption. The efficacy of this practice has not been studied formally. AIM: To perform a randomized, double-blind, placebo-controlled trial of a single dose of lansoprazole (30 mg) taken prior to a large meal and alcohol consumption.
METHODS: Study subjects were recruited randomly from local primary care and hospital physicians. Each participant (n = 56; 37 male, 19 female; mean age, 38 years) completed questionnaires before and after the meal. Approximately 90 min prior to the provocative meal, participants were witnessed taking either placebo or 30 mg lansoprazole. Bar tokens were dispensed to permit the accurate quantification of alcohol consumption (mean, 15 units).
RESULTS: Forty per cent of subjects reported significant reflux symptoms. For the entire group, there was no significant difference between lansoprazole and placebo. Post-prandial reflux was more frequent in those consuming > 15 units of alcohol (13/26, 50%) compared with those consuming < 15 units (7/30, 24%; P < 0.05). In the group who consumed > 15 units of alcohol, lansoprazole was associated with a lower rate of heartburn (5/15, 33%) compared with placebo (8/11, 73%; P < 0.05).
CONCLUSION: A single dose of a proton pump inhibitor prior to indulgence was only associated with reduced heartburn in those consuming > 15 units of alcohol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641517     DOI: 10.1046/j.1365-2036.2003.01483.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Lifestyle measures in the management of gastro-oesophageal reflux disease: clinical and pathophysiological considerations.

Authors:  J H-E Kang; J Y Kang
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

2.  Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Authors:  Alice Capogrosso Sansone; Irma Convertino; Maria Teresa Galiulo; Stefano Salvadori; Stefania Pieroni; Tamara Knezevic; Stefania Mantarro; Alessandra Marino; Manfred Hauben; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

3.  Development of scores assessing the refluxogenic potential of diet of patients with laryngopharyngeal reflux.

Authors:  Jerome R Lechien; Francois Bobin; Francois Mouawad; Karol Zelenik; Christian Calvo-Henriquez; Carlos M Chiesa-Estomba; Necati Enver; Andrea Nacci; Maria Rosaria Barillari; Antonio Schindler; Lise Crevier-Buchman; Stéphane Hans; Virginie Simeone; Elzbieta Wlodarczyk; Bernard Harmegnies; Marc Remacle; Alexandra Rodriguez; Didier Dequanter; Pierre Eisendrath; Giovanni Dapri; Camille Finck; Petros Karkos; Hillevi Pendleton; Tareck Ayad; Vinciane Muls; Sven Saussez
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-12       Impact factor: 2.503

Review 4.  Body weight, lifestyle, dietary habits and gastroesophageal reflux disease.

Authors:  Davide Festi; Eleonora Scaioli; Fabio Baldi; Amanda Vestito; Francesca Pasqui; Anna Rita Di Biase; Antonio Colecchia
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

5.  Dietary intake and risk for reflux esophagitis: a case-control study.

Authors:  Ping Wu; Xiao-Hu Zhao; Zi-Sheng Ai; Hui-Hui Sun; Ying Chen; Yuan-Xi Jiang; Yi-Li Tong; Shu-Chang Xu
Journal:  Gastroenterol Res Pract       Date:  2013-04-16       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.